TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29400576

Group type: EXPERIMENTAL
Intervention: Salt substitute
Number of subjects: 220

Group type: COMPARATOR
Intervention: Regular salt
Number of subjects: 220
Study: 28078860

Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural block
Number of subjects: 24

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 24
Study: 25076084

Group type: EXPERIMENTAL
Intervention: Needling
Number of subjects: 37

Group type: COMPARATOR
Intervention: Liquid nitrogen cryotherapy
Number of subjects: 37
Study: 21692869

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 28
Study: 20593247

Group type: EXPERIMENTAL
Intervention: Systemic inflammatory response syndrome (SIRS)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: SIRS burden (number of SIRS variables per day over the first 4 days)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Neurosurgical clipping vs. endovascular coiling
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: SIRS
Number of subjects: 413
Study: 17437502

Group type: EXPERIMENTAL
Intervention: Home fecal occult blood test (FOBT)
Number of subjects: 1808

Group type: EXPERIMENTAL
Intervention: Screening endoscopy
Number of subjects: 1808

Group type: EXPERIMENTAL
Intervention: Overall CRC screening
Number of subjects: 1808

Group type: EXPERIMENTAL
Intervention: Doctor's recommendation for screening
Number of subjects: 1808
Study: 15389228

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) 500 mg immediately before the procedure
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study: 11437760

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 90 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 60 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9520235

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 21
Study: 7925519

Group type: EXPERIMENTAL
Intervention: Nifedipine CC (40 mg oral dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2768942

Group type: EXPERIMENTAL
Intervention: Lymph node dissection
Number of subjects: 183

Group type: COMPARATOR
Intervention: No lymph node dissection
Number of subjects: 183
Study: 63748

Group type: EXPERIMENTAL
Intervention: sulphafurazole (sulfisoxazole), 500 mg orally q.i.d. for 10 days
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: aminocyclitols (streptomycin or spectinomycin), 2 g intramuscularly for 1 to 3 doses at 12 h intervals
Number of subjects: 91

Group type: COMPARATOR
Intervention: C+U+ N.G.U.
Number of subjects: 91
Study: 30661559

Group type: EXPERIMENTAL
Intervention: Naturalistic cognitive behavioral therapy (CBT)
Number of subjects: 1092
Study: 28098099

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) levels
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Interleukin-10 (IL-10) levels
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Metabolic acidosis and serum bicarbonate levels
Number of subjects: 84
Study: 25864152

Group type: EXPERIMENTAL
Intervention: Monetary incentives to eat
Number of subjects: 353

Group type: COMPARATOR
Intervention: Monetary incentives not to eat
Number of subjects: 353
Study: 23568940

Group type: EXPERIMENTAL
Intervention: Opt-in consent (n = 564)
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Opt-out consent (n = 565)
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: Overall support for data linkage
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: Trust in privacy protections
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: Parental concerns about serious reactions
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: Preference for consent type
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: Immunization status of babies
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: Trust in vaccine safety
Number of subjects: 1129
Study: 21915570

Group type: EXPERIMENTAL
Intervention: Active pulsed electromagnetic field device
Number of subjects: 259

Group type: COMPARATOR
Intervention: Inactive pulsed electromagnetic field device (placebo)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Active pulsed electromagnetic field device (compliant group)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Combined placebo and active, noncompliant group
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Active and placebo groups (overall)
Number of subjects: 259
Study: 19828711

Group type: EXPERIMENTAL
Intervention: Iron-fortified milk (1.5 mg iron/100 g prepared milk)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Red meat (approximately 2.6 mg iron from red meat dishes daily)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control (nonfortified milk with 0.01 mg iron/100 g prepared milk)
Number of subjects: 225
Study: 16760795

Group type: EXPERIMENTAL
Intervention: ART + three 5-day cycles of IL-2 at 4.5 million U, Sc, BID every 8 weeks (n = 23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: ART alone (n = 24)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both arms (IL-2 and ART alone)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IL-2 before TI
Number of subjects: 47
Study: 16228176

Group type: EXPERIMENTAL
Intervention: Pressure support
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: T-piece
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: T-piece with heliox
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Extubation
Number of subjects: 17

Group type: COMPARATOR
Intervention: T-piece ventilation
Number of subjects: 17
Study: 12386642

Group type: EXPERIMENTAL
Intervention: ASIS (400 microg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10423226

Group type: EXPERIMENTAL
Intervention: Brand N (RMP + INH tablet)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Brand R (reference brand R, RMP + INH tablet)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Brand L (RMP + INH capsule)
Number of subjects: 12
Study: 7576325

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (AP), > or = 10 prophylactic aerosols
Number of subjects: 49

Group type: COMPARATOR
Intervention: Aerosolized pentamidine (AP), first exposure
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no aerosolized pentamidine)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (AP), long-term exposure
Number of subjects: 49
Study: 2149088

Group type: EXPERIMENTAL
Intervention: Fenoterol 200 micrograms
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fenoterol 800 micrograms
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ipratropium bromide 40 micrograms
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ipratropium bromide 160 micrograms
Number of subjects: 15
Study: 92091

Group type: EXPERIMENTAL
Intervention: Megestrol (Megace, 120 mg./day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Megestrol
Number of subjects: 61
Study: 31000658

Group type: EXPERIMENTAL
Intervention: Randomized measurements for probing second-order RÃ©nyi entropy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Presence of disorder
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Absence of disorder
Number of subjects: 10
Study: 28470117

Group type: EXPERIMENTAL
Intervention: Standardized yoga intervention (8-week program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 26248248

Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS) protocol
Number of subjects: 116

Group type: COMPARATOR
Intervention: Non-FTS postoperative care
Number of subjects: 116
Study: 23471856

Group type: EXPERIMENTAL
Intervention: Subcutaneous skin elevation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sub-SMAS skin elevation
Number of subjects: 30
Study: 22134057

Group type: EXPERIMENTAL
Intervention: A-Zn toothpaste
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: B-experimental toothpaste (Zn citrate + PVM/MA copolymer)
Number of subjects: 28

Group type: COMPARATOR
Intervention: C-control toothpaste without Zn
Number of subjects: 28
Study: 19124628

Group type: EXPERIMENTAL
Intervention: Vitamin B12 (1000 mcg sublingual) for 6 months
Number of subjects: 58
Study: 17605487

Group type: EXPERIMENTAL
Intervention: Plasma light curing
Number of subjects: 25

Group type: COMPARATOR
Intervention: LED light curing
Number of subjects: 25
Study: 15151491

Group type: EXPERIMENTAL
Intervention: Individualised supervised physiotherapy treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standardised unsupervised home exercise regime
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Individualised physiotherapy treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standardised home exercise regime
Number of subjects: 58
Study: 11481625

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (0.5, 1.0, or 1.5 microg/kg, once-weekly)
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (1.5 microg/kg)
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (all doses)
Number of subjects: 1219

Group type: COMPARATOR
Intervention: interferon alfa-2b (3 MIU, three-times-weekly)
Number of subjects: 1219
Study: 9494998

Group type: EXPERIMENTAL
Intervention: Intravesical installation of 30 mg capsaicin in 100 ml of 30% alcohol
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100 ml 30% alcohol alone (control group)
Number of subjects: 12
Study: 8041178

Group type: EXPERIMENTAL
Intervention: Vitamin E (alpha‐tocopherol)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Corn oil placebo
Number of subjects: 28
Study: 2738212

Group type: EXPERIMENTAL
Intervention: Cognitive bibliotherapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Behavioral bibliotherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Delayed-treatment control
Number of subjects: 66
Study: 1098732

Group type: EXPERIMENTAL
Intervention: Metronidazole (Flagyl)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Nimorazole (Naxogin)
Number of subjects: 218
Study: 31329189

Group type: EXPERIMENTAL
Intervention: Complex non-drug programs including exercise therapy, mineral water, multivitamins, minerals, and physiotherapy (vibrotherapy, chromotherapy, melotherapy, aromatherapy, aeroionotherapy)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Complex non-drug programs including vibrotherapy, chromotherapy, melotherapy, aromatherapy, and aeroionotherapy
Number of subjects: 330

Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 330
Study: 27900515

Group type: EXPERIMENTAL
Intervention: AFEP enhanced with the '10 Keys'™ to Healthy Aging
Number of subjects: 462

Group type: COMPARATOR
Intervention: AFEP alone
Number of subjects: 462
Study: 26002493

Group type: EXPERIMENTAL
Intervention: Classical LLETZ operation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resection of the lesion only
Number of subjects: 0
Study: 24431855

Group type: EXPERIMENTAL
Intervention: Open rhinoplasty
Number of subjects: 36

Group type: COMPARATOR
Intervention: Closed rhinoplasty
Number of subjects: 36
Study: 21816868

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1094
Study: 19796594

Group type: EXPERIMENTAL
Intervention: Povidine‐iodine 1% with isopropyl alcohol 23%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 0.5% with isopropyl alcohol 70%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bristled brush pre-treatment
Number of subjects: 50
Study: 16839845

Group type: EXPERIMENTAL
Intervention: ACTH1-24 1 mg IM, daily for 4 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cortisol 150 mg ID (50 mg tid) daily for 4 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group observed for 4 days
Number of subjects: 30
Study: 15486187

Group type: EXPERIMENTAL
Intervention: Doxorubicin (75 mg/m² q3wks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Docetaxel (100 mg/m² q3wks)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Doxorubicin (topo-II tumor content >10%)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: HER-2 status
Number of subjects: 108
Study: 11305983

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Overall population (diabetics vs nondiabetics)
Number of subjects: 125

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 125

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 125
Study: 9310126

Group type: EXPERIMENTAL
Intervention: lenograstim 10 micrograms/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: filgrastim 10 micrograms/kg
Number of subjects: 32
Study: 7680995

Group type: EXPERIMENTAL
Intervention: 2.9 g piracetam
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 4.8 g piracetam
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 9.6 g piracetam
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 3535660

Group type: EXPERIMENTAL
Intervention: Cyclacillin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 80
Study: 29426677

Group type: EXPERIMENTAL
Intervention: Alfaxalone (ALF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propofol (PRO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alfaxalone + Acepromazine and Butorphanol (ALF–AB)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propofol + Acepromazine and Butorphanol (PRO–AB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acepromazine and Butorphanol (AB)
Number of subjects: 10
Study: 26590067

Group type: EXPERIMENTAL
Intervention: Simulation training on porcine cadaver
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional training per routine residency rotations
Number of subjects: 22
Study: 25182161

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure lowering treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systolic blood pressure
Number of subjects: 0
Study: 22364430

Group type: EXPERIMENTAL
Intervention: Caring Skills: Working with Mental Illness training program delivered on the Internet, duration 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20557392

Group type: EXPERIMENTAL
Intervention: Nurse-led case management programme (comprehensive education and 6-week nurse-initiated telephone follow-up)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Routine hospital discharge services (control group)
Number of subjects: 85
Study: 18543037

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with Epidoxorubicin, Etoposide, and Cisplatin (EEP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Surgery with postoperative chemotherapy alone (previously studied controls)
Number of subjects: 24
Study: 16317129

Group type: EXPERIMENTAL
Intervention: Higher length-for-age and weight-for-length Z-scores, no anemia, and meat consumption
Number of subjects: 485

Group type: COMPARATOR
Intervention: Lower length-for-age and weight-for-length Z-scores, presence of anemia, and no meat consumption
Number of subjects: 485
Study: 12744488

Group type: EXPERIMENTAL
Intervention: 20 mg/day enalapril for 5 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Single dose of 20 mg enalapril 2 h before LPS infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11223318

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Effective treatment included in trial protocol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Protocol/Hawthorne effect
Number of subjects: 21
Study: 9551704

Group type: EXPERIMENTAL
Intervention: Valsartan alone (160 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cimetidine alone (800 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Valsartan 1 h after cimetidine
Number of subjects: 12
Study: 7938284

Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sonography
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 29
Study: 2451385

Group type: COMPARATOR
Intervention: Local UVB irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole body UVB irradiation combined with additional irradiation of the hands
Number of subjects: 0
Study: 30704214

Group type: EXPERIMENTAL
Intervention: Single-tract reconstruction group (n=41)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Double-tract reconstruction group (n=43)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 29065953

Group type: EXPERIMENTAL
Intervention: Lemborexant (1, 2.5, 5, 10, 15, 25 mg)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Lemborexant (doses > 1 mg)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Lemborexant (2.5-10 mg)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 25495490

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus ovarian suppression
Number of subjects: 3066

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 3066

Group type: EXPERIMENTAL
Intervention: Exemestane plus ovarian suppression
Number of subjects: 3066

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus ovarian suppression (in patients who received prior chemotherapy)
Number of subjects: 3066

Group type: COMPARATOR
Intervention: Tamoxifen (in patients who received prior chemotherapy)
Number of subjects: 3066
Study: 22939048

Group type: EXPERIMENTAL
Intervention: Team and leaders‐directed strategy
Number of subjects: 2733

Group type: COMPARATOR
Intervention: State‐of‐the‐art strategy
Number of subjects: 2733

Group type: EXPERIMENTAL
Intervention: Comparison of both strategies
Number of subjects: 2733
Study: 21731866

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo three times a day
Number of subjects: 80
Study: 19379098

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide dry-mist disinfection system
Number of subjects: 748

Group type: COMPARATOR
Intervention: 0.5% sodium hypochlorite solution
Number of subjects: 748
Study: 16489082

Group type: EXPERIMENTAL
Intervention: Concurrent docetaxel plus vaccine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vaccine alone
Number of subjects: 28
Study: 15038906

Group type: EXPERIMENTAL
Intervention: Midwife examination
Number of subjects: 826

Group type: COMPARATOR
Intervention: Senior House Officer (SHO) examination
Number of subjects: 826
Study: 11202309

Group type: EXPERIMENTAL
Intervention: Surgical treatment with multimodal therapy including chemotherapy
Number of subjects: 3696

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 3696

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 3696
Study: 9148719

Group type: EXPERIMENTAL
Intervention: Odstock dropped foot stimulator (ODFS)
Number of subjects: 56
Study: 7918155

Group type: EXPERIMENTAL
Intervention: rhSOD (200 mg intravenously during surgery)
Number of subjects: 100
Study: 31676953

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus FOLFIRI
Number of subjects: 529
Study: 29457429

Group type: EXPERIMENTAL
Intervention: Stiletto needle treatment once a week for 2 weeks
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Needle-knife treatment once a week for 2 weeks
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Voltaren treatment (votalin emulsion smearing 3 to 5 cm on painful area of knee joint, three times a day for 2 weeks)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 113
Study: 25372235

Group type: EXPERIMENTAL
Intervention: High call completion group
Number of subjects: 151

Group type: COMPARATOR
Intervention: Low call completion group
Number of subjects: 151
Study: 22821361

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2b plus ribavirin (Peg‐IFN‐α2b/RBV)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 79
Study: 21490326

Group type: EXPERIMENTAL
Intervention: Intravenous fat emulsion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study: 18289189

Group type: EXPERIMENTAL
Intervention: Critical Care Nurses (CCNs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medical Doctors (MDs)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (CCNs and MDs)
Number of subjects: 60
Study: 16488901

Group type: EXPERIMENTAL
Intervention: Acetic acid (5%) iontophoresis combined with LowDye taping
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.4%) iontophoresis combined with LowDye taping
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl) iontophoresis combined with LowDye taping
Number of subjects: 31
Study: 12883232

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg/d for 14 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10868320

Group type: EXPERIMENTAL
Intervention: ECT x 2 (twice weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECT x 3 (three times weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulated ECT (control group)
Number of subjects: 0
Study: 9273452

Group type: EXPERIMENTAL
Intervention: Endoscopic release
Number of subjects: 178

Group type: COMPARATOR
Intervention: Open release
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 178
Study: 8255453

Group type: EXPERIMENTAL
Intervention: 5% dextrose in water (D5W)
Number of subjects: 748

Group type: COMPARATOR
Intervention: Half normal saline (0.45S)
Number of subjects: 748
Study: 2870753

Group type: EXPERIMENTAL
Intervention: Active neuroleptic medication
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 28498490

Group type: EXPERIMENTAL
Intervention: Semi-parametric hierarchical mixture model for gene screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regression models with covariates representing subgroups
Number of subjects: 0